AFLAC Incorporated vs SOLAI Limited — how do they compare? AFLAC Incorporated trades at $120.6 (market cap $60.70B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: AFLAC Incorporated is far larger — about 3636.9× SOLAI Limited's market cap, and AFLAC Incorporated pays a 2.02% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| AFL | SLAI | |
|---|---|---|
Market Cap | $60.70B | $16.69M |
Sector | Financials | Technology |
52-Week High | $129.55 | $26.74 |
52-Week Low | $103.55 | $2.74 |
Enterprise Value | $70.65B | $16.33M |
Dividend Yield | 2.02% | — |
Signals from Pluang's Aura AI — not financial advice
AFL trades at $120.98, down 0.79% on the day, with a P/E of 13.06 and net income margin of 26.59%. Recent earnings missed estimates for three consecutive quarters, with Q3 2026 results pending. Technical indicators show a bullish overall signal despite bearish moving averages and oscillators. The company maintains a strong dividend history, with recent payouts of $0.61 per share.
Outlook remains mixed; solid profitability and dividend growth support income investors, but earnings misses and revenue declines pose near-term risks. Analyst consensus is cautious with a hold-heavy rating and price target of $118, slightly below current levels. Key catalysts include U.S. sales momentum and Japan unit performance, while currency headwinds and medical cost inflation are concerns.
SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.
The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.
Trailing returns across standard periods
Latest headlines on both assets
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →